Drug intelligence / Profile preview

RT307

Development stage: Preclinical
Lead developer: Revio Therapeutics
Modality: Drug Delivery Systems, Small Molecules
Administration: Oral

Overview

**RT307** is a preclinical, orally administered fixed-dose combination capsule being developed by Revio Therapeutics for an unspecified autoimmune disease indication. Revio identifies the program as a reformulation; the component active substances, molecular targets, and mechanism of action have not been publicly disclosed.

Beyond the preview

Go deeper on RT307.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RT307.

Explore the full profile